• VIDEO: Examining adjuvant chemotherapy in locally advanced cervical cancer

    2 monthes ago - By Healio

    In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed the “practice-changing” results from the OUTBACK trial.
    Researchers designed the international, randomized, phase 3 trial, which was presented during a plenary session at the ASCO Annual Meeting, to evaluate the potential survival benefit of adjuvant chemotherapy given after standard chemoradiation compared with chemoradiation alone in patients with locally advanced cervical cancer.
    After 5 years, the data showed no difference in progression-free survival between the two
    Read more ...

     

  • VIDEO: Study evaluates adjuvant bevacizumab duration in ovarian cancer

    VIDEO: Study evaluates adjuvant bevacizumab duration in ovarian cancer

    2 monthes ago - By Healio

    In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, spoke with Healio about findings from a study examining survival with longer vs. shorter duration of bevacizumab therapy in patients with advanced ovarian cancer.
    For the study, the researchers randomly assigned patients to receive adjuvant bevacizumab for 15 or 30 months.
    Both regimens were generally well tolerated, Annunziata noted, but OS was “essentially the same” between treatment arms.
    “The conclusion from this study is that 15 months of bevacizumab
    Read more ...

     

  • VIDEO: Less intense follow-up adequate in endometrial cancer

    VIDEO: Less intense follow-up adequate in endometrial cancer

    2 monthes ago - By Healio

    In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed results from the TOTEM trial presented at the ASCO Annual Meeting.
    Researchers designed TOTEM to compare intensive follow-up with minimalist follow-up in patients who were surgically treated for endometrial cancer and were in complete clinical remission. They stratified patients according to whether they had a low or high risk for recurrence and then randomly assigned patients to intensive or minimalist follow-up regimens.
    In both high- and low-risk patients, intensive follow-up did
    Read more ...